LEI 5493008L4LMIPBW5KO36

Takeda Pharmaceuticals International AG

Group parent: 武田薬品工業株式会社4502 · JT

Awards tracked

32

Value

—

Countries

CH

Download sample CSV

Contract awards & public grants

GUIDE-AI – Guiding your treatment with current evidence → TAKEDA PHARMACEUTICALS INTERNATIONAL AG

European Commission · CH · Grant · 2025-12-17

—

Breakthrough Regulatory Innovation and Development throuGh sandbox Environments → TAKEDA PHARMACEUTICALS INTERNATIONAL AG

European Commission · CH · Grant · 2025-11-07

—

Verification and validation of a biomarker panel that identifies individuals at high risk to develop Crohn’s disease allowing INTERCEPTION of full-blo → TAKEDA PHARMACEUTICALS INTERNATIONAL AG

European Commission · CH · Grant · 2025-01-17

—

Propelling the shift toward the future of circular, safe and sustainable packaging and single use device ecoDesigned solutions through healthcare envi → TAKEDA PHARMACEUTICALS INTERNATIONAL AG

European Commission · CH · Grant · 2024-12-18

—

REpresentative Clinical Research - ADvancing Inclusivity in Europe → TAKEDA PHARMACEUTICALS INTERNATIONAL AG

European Commission · CH · Grant · 2024-12-05

—

Synthetic hEalthcare dAta goveRnanCe Hub → TAKEDA PHARMACEUTICALS INTERNATIONAL AG

European Commission · CH · Grant · 2024-09-13

—

Developing and implementing VIrtual Control groups To reducE animal use in toxicology Research → TAKEDA PHARMACEUTICALS INTERNATIONAL AG

European Commission · CH · Grant · 2024-07-26

—

Integration of heterogeneous Data and Evidence towards Regulatory and HTA Acceptance → TAKEDA PHARMACEUTICALS INTERNATIONAL AG

European Commission · CH · Grant · 2023-05-10

—

European platform for neurodegenerative disorders → TAKEDA PHARMACEUTICALS INTERNATIONAL AG

European Commission · CH · Grant · 2021-10-25

—

Shortening the path to rare disease diagnosis by using newborn genetic screening and digital technologies → TAKEDA PHARMACEUTICALS INTERNATIONAL AG

European Commission · CH · Grant · 2021-10-13

—

FrAmework for ClInicaL trIal participants daTA reutilization for a fully Transparent and Ethical ecosystem → TAKEDA PHARMACEUTICALS INTERNATIONAL AG

European Commission · CH · Grant · 2021-10-11

—

BEhavioral and Adherence Model for improving quality, health outcomes and cost-Effectiveness of healthcaRe → TAKEDA PHARMACEUTICALS INTERNATIONAL AG

European Commission · CH · Grant · 2021-09-27

—

Innovations to accelerate vaccine development and manufacture → TAKEDA PHARMACEUTICALS INTERNATIONAL AG

European Commission · CH · Grant · 2021-07-19

—

Accelerating Development and Improving Access to CAR and TCR-engineered T cell therapy → TAKEDA PHARMACEUTICALS INTERNATIONAL AG

European Commission · CH · Grant · 2020-11-24

—

Accelerating Research & Development for Advanced Therapies → TAKEDA PHARMACEUTICALS INTERNATIONAL AG

European Commission · CH · Grant · 2020-11-11

—

COVID-19 infections - Remote Early Detection → TAKEDA PHARMACEUTICALS INTERNATIONAL AG

European Commission · CH · Grant · 2020-10-16

—

H2O Health Outcomes Observatory → TAKEDA PHARMACEUTICALS INTERNATIONAL AG

European Commission · CH · Grant · 2020-09-30

—

Corona Accelerated R&D in Europe → TAKEDA PHARMACEUTICALS INTERNATIONAL AG

European Commission · CH · Grant · 2020-08-07

—

EUbOPEN: Enabling and Unlocking biology in the OPEN → TAKEDA PHARMACEUTICALS INTERNATIONAL AG

European Commission · CH · Grant · 2020-05-11

—

Identifying Digital Endpoints to Assess FAtigue, Sleep and acTivities in daily living in Neurodegenerative disorders and Immune-mediated inflammatory → TAKEDA PHARMACEUTICALS INTERNATIONAL AG

European Commission · CH · Grant · 2019-12-18

—

Immune-Image: Specific Imaging of Immune Cell Dynamics Using Novel Tracer Strategies → TAKEDA PHARMACEUTICALS INTERNATIONAL AG

European Commission · CH · Grant · 2019-09-26

—

Identification of the Molecular Mechanisms of non-response to Treatments, Relapses and Remission in Autoimmune, Inflammatory, and Allergic Conditions → TAKEDA PHARMACEUTICALS INTERNATIONAL AG

European Commission · CH · Grant · 2019-08-22

—

Trials@Home: Center of Excellence – Remote Decentralised Clinical Trials → TAKEDA PHARMACEUTICALS INTERNATIONAL AG

European Commission · CH · Grant · 2019-08-07

—

Building an ecosystem for better monitoring and communicating of medication safety in pregnancy and breastfeeding: validated and regulatory endorsed w → TAKEDA PHARMACEUTICALS INTERNATIONAL AG

European Commission · CH · Grant · 2019-05-06

—

Connecting digital mobility assessment to clinical outcomes for regulatory and clinical endorsement → TAKEDA PHARMACEUTICALS INTERNATIONAL AG

European Commission · CH · Grant · 2019-03-22

—

EBiSC2 – A sustainable European Bank for induced pluripotent Stem Cells → TAKEDA PHARMACEUTICALS INTERNATIONAL AG

European Commission · CH · Grant · 2019-02-28

—

Efficiently Networking European Neurodegeneration Research → TAKEDA PHARMACEUTICALS INTERNATIONAL AG

European Commission · CH · Grant · 2019-02-28

—

Remote Assessment of Disease and Relapse – Alzheimer’s Disease → TAKEDA PHARMACEUTICALS INTERNATIONAL AG

European Commission · CH · Grant · 2018-12-05

—

The GetReal Initiative → TAKEDA PHARMACEUTICALS INTERNATIONAL AG

European Commission · CH · Grant · 2018-06-26

—

Liver Investigation: Testing Marker Utility in Steatohepatitis → TAKEDA PHARMACEUTICALS INTERNATIONAL AG

European Commission · CH · Grant · 2017-10-09

—

Healthcare Alliance for Resourceful Medicines Offensive against Neoplasms in HematologY - Sofia ref.: 116026 → TAKEDA PHARMACEUTICALS INTERNATIONAL AG

European Commission · CH · Grant · 2016-12-22

—

Patient Preferences in benefit risk assessments during the drug life cycle - Sofia ref.: 115966 → TAKEDA PHARMACEUTICALS INTERNATIONAL AG

European Commission · CH · Grant · 2016-10-21

—

Entity identity is matched from published recipient names and registry IDs to GLEIF legal-entity records; matches can be imperfect. Source records are public procurement and grant notices.